Jiangsu Hengrui Medicine Co., Ltd.

This study tested whether adding rivoceranib to camrelizumab (a type of immunotherapy) works better than camrelizumab alone to keep liver cancer from returning after surgery or ablation. It involved 251 patients with hepatocellular carcinoma at high risk of recurrence. The main g…

This study tested a new oral drug, pyrotinib, against standard chemotherapy (docetaxel) in 151 people with advanced non-squamous lung cancer that has a specific HER2 mutation and has stopped responding to platinum chemo. The goal was to see if pyrotinib could better delay cancer …